Zacks Research Has Bullish Estimate for CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Zacks Research lifted their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued on Tuesday, November 26th. Zacks Research analyst R. Department now forecasts that the company will post earnings of ($5.20) per share for the year, up from their previous estimate of ($6.13). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.27) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.47) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.61) EPS, Q1 2026 earnings at ($1.28) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.25) EPS and FY2026 earnings at ($2.24) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the previous year, the firm earned ($1.41) earnings per share.

CRSP has been the subject of a number of other research reports. Chardan Capital lowered their target price on shares of CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reissued a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Barclays lowered their target price on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Finally, Truist Financial dropped their target price on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Stock Performance

Shares of NASDAQ CRSP opened at $50.84 on Thursday. The company’s 50 day moving average price is $48.05 and its 200-day moving average price is $51.69. CRISPR Therapeutics has a 52-week low of $43.42 and a 52-week high of $91.10. The company has a market capitalization of $4.34 billion, a P/E ratio of -17.96 and a beta of 1.67.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 1.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is owned by insiders.

Institutional Trading of CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Global Trust Asset Management LLC grew its stake in CRISPR Therapeutics by 150.0% in the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock valued at $27,000 after purchasing an additional 300 shares during the period. Larson Financial Group LLC grew its position in CRISPR Therapeutics by 95.5% during the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after buying an additional 276 shares during the period. GPS Wealth Strategies Group LLC increased its holdings in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after buying an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. bought a new stake in CRISPR Therapeutics in the second quarter worth about $35,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics in the third quarter valued at about $40,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.